NO20013638L - Acetyleniske sulfonamidtiol-TACE-inhibitorer - Google Patents

Acetyleniske sulfonamidtiol-TACE-inhibitorer

Info

Publication number
NO20013638L
NO20013638L NO20013638A NO20013638A NO20013638L NO 20013638 L NO20013638 L NO 20013638L NO 20013638 A NO20013638 A NO 20013638A NO 20013638 A NO20013638 A NO 20013638A NO 20013638 L NO20013638 L NO 20013638L
Authority
NO
Norway
Prior art keywords
tace inhibitors
thiol
acetylenic
acetylenic sulfonamide
sulfonamide thiol
Prior art date
Application number
NO20013638A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013638D0 (no
Inventor
Jeremy Ian Levin
James Ming Chen
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20013638D0 publication Critical patent/NO20013638D0/no
Publication of NO20013638L publication Critical patent/NO20013638L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/53Organo-phosphine oxides; Organo-phosphine thioxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
NO20013638A 1999-01-27 2001-07-24 Acetyleniske sulfonamidtiol-TACE-inhibitorer NO20013638L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23839399A 1999-01-27 1999-01-27
PCT/US2000/002143 WO2000044716A1 (en) 1999-01-27 2000-01-27 Acetylenic sulfonamide thiol tace inhibitors

Publications (2)

Publication Number Publication Date
NO20013638D0 NO20013638D0 (no) 2001-07-24
NO20013638L true NO20013638L (no) 2001-07-24

Family

ID=22897697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013638A NO20013638L (no) 1999-01-27 2001-07-24 Acetyleniske sulfonamidtiol-TACE-inhibitorer

Country Status (21)

Country Link
EP (1) EP1149074B1 (zh)
JP (1) JP2002535386A (zh)
KR (1) KR20010101691A (zh)
CN (1) CN1224612C (zh)
AT (1) ATE280152T1 (zh)
AU (1) AU766192B2 (zh)
BR (1) BR0007727A (zh)
CA (1) CA2356480A1 (zh)
CZ (1) CZ20012545A3 (zh)
DE (1) DE60015079T2 (zh)
DK (1) DK1149074T3 (zh)
EA (1) EA200100811A1 (zh)
ES (1) ES2230064T3 (zh)
HK (1) HK1038915A1 (zh)
HU (1) HUP0105282A3 (zh)
IL (1) IL144347A0 (zh)
NO (1) NO20013638L (zh)
NZ (1) NZ512306A (zh)
PL (1) PL350420A1 (zh)
WO (1) WO2000044716A1 (zh)
ZA (1) ZA200105069B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194209T3 (es) * 1996-07-22 2003-11-16 Monsanto Co Inhibidores de metaloproteasa de tiol sulfona.
NZ333825A (en) * 1996-07-22 2000-10-27 Monsanto Co Metalloprotease inhibitors particularly MMP-13

Also Published As

Publication number Publication date
HUP0105282A3 (en) 2005-04-28
HUP0105282A2 (hu) 2002-05-29
HK1038915A1 (zh) 2002-04-04
EP1149074A1 (en) 2001-10-31
BR0007727A (pt) 2001-10-30
AU766192B2 (en) 2003-10-09
CA2356480A1 (en) 2000-08-03
DK1149074T3 (da) 2005-01-10
NZ512306A (en) 2003-10-31
WO2000044716A1 (en) 2000-08-03
NO20013638D0 (no) 2001-07-24
KR20010101691A (ko) 2001-11-14
DE60015079T2 (de) 2005-03-03
AU2741700A (en) 2000-08-18
CN1337947A (zh) 2002-02-27
PL350420A1 (en) 2002-12-16
CZ20012545A3 (cs) 2002-04-17
ZA200105069B (en) 2002-09-20
ES2230064T3 (es) 2005-05-01
EA200100811A1 (ru) 2002-12-26
EP1149074B1 (en) 2004-10-20
JP2002535386A (ja) 2002-10-22
IL144347A0 (en) 2002-05-23
ATE280152T1 (de) 2004-11-15
DE60015079D1 (de) 2004-11-25
CN1224612C (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
WO2000044709A3 (en) ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
DE60015079D1 (de) Acetylenische sulfonamid-thiol-tace-inhibitoren
MY136789A (en) Metalloproteinase inhibitors
DK0934310T3 (da) Thiosyreafledte, monocykliske forbindelser som antikoaguleringsmidler
DK1149092T3 (da) 4- og 5-alkynyloxindoler og 4- og 5-alkenyloxindoler
NZ512446A (en) Alkynyl containing hydroxamic acid compounds as TACE inhibitors
NZ511885A (en) 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE)
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
ATE271540T1 (de) Acetylenische arylsulfonamid- und phosphinsäureamid-hydroxamsäure-derivate als tace inhibitoren
MY134437A (en) Process for lowering level of salt required for dilution thickening
WO1999037291A3 (de) Verwendung von substituierten sulfonamiden als antivirale mittel und neue stoffe
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
EA200100808A1 (ru) ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
MXPA04004010A (es) Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
EA200100805A1 (ru) Ингибиторы tace на основе гетероарилацетиленсульфонамида и фосфинамида гидроксамовой кислоты
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
NO20014845L (no) Anvendelse av arylalkanoylpyridaziner
ATE303390T1 (de) Sulfat von cephemverbindung
Kutuk et al. Solvent effects on the solvolyses of N-benzoyl-arenesulfonimidoyl chlorides
DK0691986T3 (da) Hidtil ukendte fremgangsmåder og mellemproduktforbindelser til fremstillingen af blodpladeglycoprotein IIb/IIIa-inhibitorer
BR0003334A (pt) Processo de produção de peptìdeo entomotóxico da canatoxina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application